KRAS and colorectal carcinoma: Studies by Osumi [37], or Rachiglio [46] used commercial OncomineTM NGS panels (Life Technologies, covering 14 genes or 22 genes, respectively) to detect KRAS or All-RAS status in cfDNA samples of CRC patients, and the sensitivity was 80.6% or 63.2%, and specificity was 81.5% or 100%, respectively.